TrialThe Lancet. Infectious diseases2020

Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.

Michelle J Groome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.